Clinical trials: First Relapse
Advanced Malignant Neoplasm
First-in-Human Study of KO-947 in Non-Hematological Malignancies
This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological…
- Trial name
- NCT03051035
- Testing
- KO-947
- Where
- 5 sites in United States, Spain
- Volunteers
- 61 people
- Sponsor
- Kura Oncology, Inc.
Lung Cancer
Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy
RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill non-small cell lung cancer cells.
- Trial name
- NCT00503568
- Testing
- Ad100-gp96Ig-HLA A1
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Miami
Fallopian Tube Cancer, Peritoneal Neoplasms
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
This study will develop a blood test that can be used to predict a relapse of ovarian, peritoneal, or fallopian tube cancer. The type of testing is called proteomics, or the study of proteins in living cells.
- Conditions
- Fallopian Tube Cancer, Peritoneal Neoplasms, Epithelial Ovarian Cancer
- Trial name
- NCT00086567
- Where
- 11 sites in United States
- Volunteers
- 119 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
The efficacy of single agent liposomal doxorubicin as compared to single agent docetaxel will be evaluated as first line treatment in metastatic breast cancer patients, with subsequent crossover to the opposite arm at disease…
- Trial name
- NCT00193037
- Testing
- Liposomal Doxorubicin, Docetaxel
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- SCRI Development Innovations, LLC
Relapsed/Refractory Multiple Myeloma
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT03309111
- Testing
- ISB 1342
- Where
- 20 sites in United States, France
- Volunteers
- 81 people
- Sponsor
- Ichnos Sciences SA
Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or…
- Conditions
- Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT04665765
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- City of Hope Medical Center
Anorexia Nervosa
Efficacy of a Phone-based Relapse Prevention for Anorexia Nervosa After a First Hospitalization
Anorexia Nervosa (AN) is a highly challenging disease which consequences are serious. Relapse rate is estimated between 38 and 41% during the year following hospitalization.
- Trial name
- EATLINE (NCT04102475)
- Testing
- Eatline, Control
- Where
- 6 sites in France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Lille
Bone Sarcoma, Osteosarcoma
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Randomized, non-comparative, multicentre exploratory phase II study. Two arms concerning patients with bone sarcoma after the first line therapy: in the first arm, patients will be treated with Regorafenib for a maximum of 12…
- Conditions
- Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma
- Trial name
- REGOSTA (NCT04055220)
- Testing
- Treatment by Regorafenib, Surveillance
- Where
- 16 sites in France
- Volunteers
- 168 people
- Sponsor
- Centre Leon Berard
Hodgkin Disease
Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma
The aim of this study is to analyze the efficacy of O-ESHAP treatment for Hodgkin's lymphome patients that have a first line chemotherapy treatment failure due to refractoriness, partial response or relapsed.
- Trial name
- NCT01195766
- Testing
- Ofatumumab
- Where
- 14 sites in Spain
- Volunteers
- 64 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
B-Cell Lymphoma
Study of TG-1801 in Subjects With B-Cell Lymphoma
Phase 1 first in human Study to Assess the Bispecific Antibody TG-1801 in Subjects with B-Cell Lymphoma
- Trial name
- NCT03804996
- Testing
- TG-1801, Ublituximab
- Where
- 3 sites in Australia
- Volunteers
- 50 people
- Sponsor
- TG Therapeutics, Inc.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Surgery for Relapsed Ovarian Cancer in Precision
This multicenter, biomarker-driven, patient-centric study aimed to evaluate the efficacy of secondary cytoreduction followed by platinum-based chemotherapy in combination with anti-PD1/CTLA-4 bispecifics therapy in patients with…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT06602063
- Testing
- surgery/chemotherapy, Iparomlimab/Tuvonralimab
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Aplastic Anemia
Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years
Outcomes for adult patients with Severe Aplastic Anemia (SAA) aged more than 40 years who are refractory or in relapse after first-line IST remain poor.
- Trial name
- APARR (NCT06646497)
- Testing
- Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow
- Where
- 26 sites in France
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer, Ovarian
Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer
The objective of the trial was to evaluate the efficacy of the association of topotecan and lapatinib in patients who failed first line platinum-based chemotherapy within 12 months.
- Conditions
- Cancer, Ovarian, Relapse, Chemotherapy
- Trial name
- TOPO-LAPA (NCT00888810)
- Testing
- TOPOTECAN, LAPATINIB
- Where
- 21 sites in France
- Volunteers
- 39 people
- Sponsor
- Centre Francois Baclesse
Large B Cell Lymphoma
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab monotherapy and, since cycle 4, they can continue with epcoritamab monotherapy…
- Trial name
- REPIFIR (NCT07126236)
- Testing
- Epcoritamab, Epcoritamab, tafasitamab and lenalidomide
- Where
- 19 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Multiple Myeloma
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 moves through the body, in…
- Trial name
- NCT07409246
- Testing
- ABBV-438
- Where
- 14 sites in United States, China and 2 more
- Volunteers
- 127 people
- Sponsor
- AbbVie
Acute Lymphoid Leukemia Relapse, Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant
Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia
The purpose of this study is to determine Maximum Tolerated Dosage (MTD), Dosage Limited Toxicities (DLT), and the Rate Phase 2 Dosage of clofarabine when used in combination with etoposide, asparaginase, mitoxantrone and…
- Trial name
- Vandevol (NCT01279096)
- Testing
- Clofarabine
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Lille
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
This phase II trial is studying how well sunitinib works in treating patients with idiopathic myelofibrosis. Sunitinib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth and by blocking…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00387426
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Relapse Multiple Myeloma
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Patients with relapsed/refractory symptomatic multiple myeloma who meet all inclusion criteria, will be randomized 1:1 to receive either standard of care chemotherapy (IKEMA or ICARIA) and dexamethasone until disease progression…
- Trial name
- FREEDOM (NCT06561854)
- Testing
- Dexamethasone
- Where
- France
- Volunteers
- 318 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Relapsed / Refractory AML, Relapsed / Refractory MDS
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
This is the first-in-human trial with BYON4413 to evaluate safety, PK, immunogenicity, and anti-leukemia activity of BYON4413 in patients with AML or MDS.
- Trial name
- NCT06359002
- Testing
- BYON4413
- Where
- 9 sites in Belgium, Netherlands and 1 more
- Volunteers
- 16 people
- Sponsor
- Byondis B.V.
Non-Hodgkin's Lymphoma
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
This multicenter, randomized, open-label, parallel-group study will evaluate the efficacy and safety of subcutaneously administered rituximab in comparison with observation only as maintenance therapy in participants with…
- Trial name
- MabCute (NCT01461928)
- Testing
- Chemotherapy (Induction Period), Rituximab
- Where
- 180 sites in Albania, Argentina and 22 more
- Volunteers
- 692 people
- Sponsor
- Hoffmann-La Roche